Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Genocea Biosciences (GNCA) Share Price
Media coverage about Genocea Biosciences (NASDAQ:GNCA) has trended somewhat positive this week, according to Accern Sentiment. Accern scores the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Genocea Biosciences earned a news impact score of 0.16 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 44.9588837941676 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the news stories that may have effected Accern’s scoring:
- Running on Empty or is Genocea Biosciences Inc (GNCA) Refueling? – Stock Press Daily (stockpressdaily.com)
- Genocea Biosciences Inc (GNCA) Ichimoku Levels Point to Negative Stock Momentum – Evergreen Caller (evergreencaller.com)
- Analysts Anticipate Genocea Biosciences, Inc. (GNCA) Will Post Earnings of -$0.46 Per Share (americanbankingnews.com)
- Genocea Biosciences, Inc. (NASDAQ:GNCA) Given Consensus Rating of “Buy” by Brokerages (americanbankingnews.com)
- Consensus score reveals Buy position in Healthcare Stock: Genocea Biosciences, Inc. (GNCA) ,Matinas BioPharma … – Street Observer (press release) (streetobserver.com)
Shares of Genocea Biosciences (NASDAQ:GNCA) traded down 1.40% on Tuesday, hitting $4.93. 115,369 shares of the stock were exchanged. The firm’s 50 day moving average price is $5.32 and its 200 day moving average price is $5.50. The firm’s market cap is $140.51 million. Genocea Biosciences has a one year low of $3.28 and a one year high of $7.29.
A number of brokerages have recently commented on GNCA. ValuEngine cut shares of Genocea Biosciences from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Cowen and Company reaffirmed an “outperform” rating and issued a $40.00 target price on shares of Genocea Biosciences in a report on Tuesday, July 25th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $18.00 target price (up from $17.00) on shares of Genocea Biosciences in a report on Tuesday, July 25th. Needham & Company LLC raised shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a report on Monday, July 24th. Finally, Zacks Investment Research cut shares of Genocea Biosciences from a “buy” rating to a “hold” rating in a report on Monday, July 17th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $16.52.
In other news, CFO Jonathan Poole sold 45,000 shares of the firm’s stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $6.00, for a total value of $270,000.00. Following the transaction, the chief financial officer now directly owns 84,247 shares in the company, valued at approximately $505,482. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 6.70% of the company’s stock.
About Genocea Biosciences
Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.
Receive News & Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.